PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume Contents, Author index and Subject index to Volume 14

PERGAMON PRESS OXFORD · NEW YORK

PT vol 14

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
R. T. Brittain—*Ware, Hertfordshire*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*London, England*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.

Annual Subscription, 1982, U.S. $700.00 including postage and insurance. 2 years, 1982/83, U.S. $1330.00.

Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3, 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1982 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear, copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 14, 1981, Numbers 1–3

CONTENTS

PAGE

Number 1

The uses of systemic chemotherapeutic agents in psoriasis: *C. J. McDonald* 1
Prodrug design: *R. E. Notari* 25
Responsiveness to drugs and hormones in the murine model of cardiac ontogenesis: *W. R. Roeske and K. Wildenthal* 55
The toxicology of molluscicides – Trifenmorph: *J. Duncan* 67
Modulation of the immune response by chemotherapy: *D. P. Braun and J. E. Harris* 89

Number 2

Assessment of rate and extent of drug absorption: *D. Cutler* 123
The human behavioral pharmacology of the common core heptapeptides: *R. J. Branconnier* 161
Role of opiate receptors and endogenous ligands in nociception: *J. J. C. Jacob and K. Ramabadran* 177
Nitroimidazole radiosensitizers: approaches to their chemical synthesis: *H. Monney, J. Parrick and R. G. Wallace* 197
Methods for quantifying the transport of drugs across brain barrier systems: *J. D. Fenstermacher, R. G. Blasberg and C. S. Patlak* 217
Tight binding inhibitors of xanthine oxidase: *R. Hille and V. Massey* 249

Number 3

Inhibition of cell wall biosynthesis by analogues of analine: *F. C. Neuhaus and W. P. Hammes* 265
Kinetics of drug–drug interactions: *L. Aarons* 321
The immunology of psoriasis: *P. R. Bergstresser and J. N. Gilliam* 345
Chemotherapy of psoriasis and other skin disorders with oral retinoids: *D. Tsambaos and C. E. Orfanos* 355
Transfer of drugs across the placenta: *W. J. Waddell and C. Marlowe* 375
Endogenous ligands and modulators of the digitalis receptor: some candidates: *R. S. Kim and F. S. LaBella* 391
Actions and interactions of ethanol with drugs on intermediary metabolism: *E. Mezey* 411
Electrophysiological effects of ethanol on the nervous system: *H. Kalant and N. Woo* 431
Peripheral and central pathways in pain: *D. L. Hammond and T. L. Yaksh* 459
Non-invasive assessment of drug action in rheumatoid arthritis and related disorders: *R. S. Amos and B. McConkey* 477

AUTHOR INDEX

Aarons, L. 321
Amos, R. S. 477

Bergstresser, P. R. 345
Blasberg, R. G. 217
Branconnier, R. J. 161
Braun, D. P. 89

Cutler, D. 123

Duncan, J. 67

Fenstermacher, J. D. 217

Gilliam, J. N. 345

Hammes, W. P. 265
Hammond, D. L. 459
Harris, J. E. 89
Hille, R. 249

Jacob, J. J. C. 177

Kalant, H. 431
Kim, R. S. 391

McConkey, B. 477
McDonald, C. J. 1
Marlowe, C. 375
Massey, V. 249
Mezey, E. 411
Monney, H. 197

Notari, R. E. 25
Neuhaus, F. C. 265

Orfanos, C. E. 355

Parrick, J. 197
Patlak, C. S. 217

Ramabadran, K. 177
Roeske, W. R. 55

Tsmabaos, D. 355

Waddell, W. J. 375
Wallace, R. G. 197
Wildenthal, K. 55
Woo, N. 431

Yaksh, T. L. 459

SUBJECT INDEX

Absorption of drugs 325–8
  altered, and pharmacokinetics 327
  area estimation methods 137–41
  assessment of rate and extent 123–59
  curve fitting methods 152
  definition 123, 124
  degradation in gut 326
  extent 124–37
  extent and multiple dosing 130–2
  extent and variable clearance 132–7
  input–response relationship 157–9
  lag-time estimation 157
  linear systems derivation 127–30
  mass balance derivation 125–7, 142–6
  measures, C_{max}, t_{max} 141
  numerical deconvolution 147–52
  plasma concentration–time profile 325
  rate assessment 141–57
  rate, non-linear disposition 146, 147
  rate, variable clearance 145, 146
  statistical moments 153–7
  Wagner–Nelson method 142–5
Acetylcholine and fetal atrial rate 56
Acne and oral retinoids 365–7
alpha$_1$ Adrenergic system, fetal cardiac contractility 62, 63
beta$_1$ Adrenergic system, fetal cardiac contractility 58–62
Adrenocorticotrophic hormone (ACTH) 163
Alafosfalin
  antibacterial activity 301
  resistance development inhibition 307
D-Alanine, cycloserine and 5-methyl substituted effects 274
Alanine analogues 267, 268
  antibacterial agents 299–311
  antibacterial spectra 300–2
  carboxypeptidases 285
  categories 268
  cell wall synthesis inhibition 265–311
  E.coli transport systems 293–5
  inhibition mechanism 278
  pharmacokinetics 308–10
  resistance acquisition 305–8
  selective toxicity 299, 300
  synergistic combinations 304, 305
  toxophore release 302–4
D-Alanine ligase
  inhibitors 266–75
  substituted cycloserine 274
Alanine racemase
  cycloserine inhibition 273, 274
  inhibition 266–75
  irreversible inactivation 270
  mechanism 269
  swinging door model 269
D-Alanyllipoteichoic acid, synthesis inhibition 291–3
Albumin, ethanol effects 414
Allopurinol
  tolerance 252, 253
  and xanthine oxidase inhibition 250–3
Alloxanthine, xanthine oxidase inhibition 250–3
D-Aminoacid transaminase
  beta-elimination model 271
  inhibitors 266–75
2-Aminoimidazoles, chemical synthesis 198–201
Ampicillin, prodrug 50
Analgesia
  neurotransmitter 185–7
  non-opioid 186, 187
  opioid 185
Ankylosing spondylitis
  clinical assessment of symptoms 485, 486
  functional capacity 486
  radiology 487
Antibacterial activity, alanine analogues 299–311
Arsenite, xanthine oxidase inhibition 261
Arthritis, assessment of childhood 489, 490
Assessment of drug action in rheumatic conditions 477–84
Autoantibodies in psoriasis 348–50
  antinuclear 348, 349
  anti-stratum corneum 349
  immune complexes 349, 350
Azaribine
  adverse reactions 15, 16
  formula 11
  metabolic action 12–14
  in psoriasis 11–16
  psoriasis treatment 14, 15
Azomycin chemistry 210

Behavioral pharmacology
  heptapeptides 161–72
  tests 164
Blood–CNS transport, CNS capillaries 239–43
Blood–CSF transport, transchoroidal flow 235–7
Bolus injections, extraction fraction 218
Brain barrier systems
  blood–CSF transport 234–7
  brain washout time 230–2
  capillary isolation 234
  CSF–brain transport 237–9
  drug transport quantification methods 217–46
  external registration technique 224, 225
  indicator diffusion 219–22
  intravenous administration and brain sampling 226–30
  transport pathways 245
  ventriculocisternal perfusion 232, 233
Brain capillaries, clearance of chemicals 242
Brain lesions and nociception 183, 184
Brain uptake index 222–4

DD-Carboxypeptidase inhibition 285–90
  exocellular activity 290
LD-Carboxypeptidase inhibition 285–90

T Vol 14

Cardiac glycosides
acceptor sites 391–4
targets 394–6
Cardiac ontogenesis
alpha$_1$ adrenergic system 62, 63
beta$_1$ adrenergic system 58–62
murine model, drug response 55–65
muscarinic cholinergic system 55
protein kinase 61
Carotenoids, natural 356, 357
Cell wall biosynthesis, inhibition by alanine analogues 265–311
Central neural substrates in pain 462–6
primary afferent neuron entry 462
spinal cord cell elements 462–4
Cephalexin-alafosfalin
pharmacokinetics 308–10
resistance inhibition 307
Choroid plexus
blood–CNS transport 243, 244
blood–CSF transport 235–7
Conduction velocity, cutaneous afferents 460, 461
CSF–brain exchange 237–9
Cyanide, xanthine oxidase inhibition 257–60
Cyanolysis, Mo=S complex 259
Cycloserine 267
alanine inhibition 273
5-methyl, effect on alanine 274

Darier's disease, oral methods 365
Desmethylmisonadizole preparation 213
Digitalis
-like-properties, endogenous ligands 392, 393, 396, 401
receptor 391–4
Dihydroalprenolol, fetal mouse heart 57–9
2, 4(5)-Dinitroimidazole 210
Dipeptide analogues and uptake inhibition 298
Dipeptide transport systems 295–8
and lysis prevention in *E.coli* 297
Distribution of drugs 328–32
administration methods 332
and plasma protein binding 329, 330
Dithranol
adverse effects 4
biochemical effects 3
formula 2
in psoriasis 2–4
DNA synthesis, drug effects 95–101
Drug–drug interaction models 321–41
multiple mechanisms 339, 340
Drugs
brain barrier transport 217–46
disposition 322
distribution and protein binding 324
ethanol interaction with intermediary metabolites 411–24
immune response modulation 89–114
multiple therapy and interactions 321–41
placenta transfer 375–87
rheumatoid arthritis 477–90

Effector cell differentiation
drug effects 103–9
non-T cell, non-B cell 111–13
T cell, drug effects 110, 111
Endogenous morphines 177–88
antinociceptive 178, 179
Endorphins, metabolic inhibition and nociception 183
Enkephalins, metabolic inhibitors and nociception 183
Ependyma and brain ECF 244–6
Ethanol
adrenal hormones 419
biphasic effects 442, 443
brain stem potentials 441
calcium in membranes 433, 434, 444, 445
carbohydrate metabolism 412, 413
chronic effects 443
and drug effects on metabolism 411–24
drug-induced hepatoticity 421
EEG activity 442, 448, 450, 451
effect on evoked responses 440–2
and folate 417
genetic factors in response 449, 452
-induced liver damage 421–4
lipid metabolism 414–16
and membrane-bound enzymes 432, 433
membrane excitability 435, 436
membrane lipid fluidization 431, 432, 443, 444
metabolism 411, 412
nervous system effects 431–52
neuronal activity in identified pathways 438–40, 446–8
neuron single unit firing 434, 435
protein metabolism 413, 414
sex hormones 420
single synapse action 437, 438, 445, 446
thiamine 416, 417
thyroid hormones 419
tolerance, acute and chronic 448, 449
and transmitter release 437, 445, 446
vitamin A effects 418
vitamin B_6 effects 417, 418
vitamin D effects 418, 419
Evans Blue Dye, indicator diffusion 220
Excretion of drugs 338, 339
reabsorption 339

Fatty acids, digitalis-like properties 397, 398
Formaldehyde, xanthine oxidase inhibition 260, 261
Funicular pathways in pain 464–6
dorsal tracts 465, 466
intersegmental links 466
ventral tracts 464, 465

Gaffkya homari, peptidoglycan synthesis and alanine analogues 276–8, 288, 289
Glucagon, fetal heart responses 63–5
Gout assessment 484, 485

Helper cell differentiation, drug effects 102, 103
Heptapeptides, common core 163
affective ratings 167, 168
electroencephalogram measures 166, 167
electrophysiological measures 167
learning and memory 169–71
psychomotor performance 168, 169
test outcome 171, 172
HLA associations in psoriasis 347 348
Hydrea 16, 17
adverse reactions 17
history 16
metabolic actions 16, 17
psoriasis treatment 17
Hypophysectomy and nociception 184

Ichthyotic condition, oral retinoids 367
Immune complexes in psoriasis 349, 350
Immune response
  afferent drug effects 89–95
  central, drug effects 95–109
  efferent, drug effects 109–13
  modulation by chemotherapy 89–114
Immunocompetence, drug effects 95
Immunology of psoriasis 345–52
Inhibitors
  cell wall biosynthesis 265–311
  xanthine oxidase 249–61
Isoproterenol, fetal mouse heart response 58

Lipids, bovine liver, digitalis-like properties 399, 400
Liver
  cell damage 422
  ethanol-induced damage 421–4
  fibrogenesis 423
  immune system and damage 423, 424
  regeneration 422
Lymphocytes, drug effects 91–5

Macrophages, drug effects 90, 91
Melanocyte stimulating hormone (MSH) 163
Membranes, ethanol effects 431–4
Memory, control processes 164, 165
3, 4, 6-Mercaptopurine-azathioprine
  psoriasis treatment 18, 19
Metabolism of drugs 332–7
  examples of inhibition 335–7
  examples of stimulation 337
  hemodynamic interactions 335
  stimulation 334, 335
Methanol, xanthine oxidase inhibition 260, 261
D-Methionine and peptidoglycan synthesis 290
Metronidazole preparation 213
Misonidazole
  chemistry 210
  synthesis 212
Models, drug–drug interaction 321–4
Molluscicides, toxicology 67–84
Monocytes, drug effects 90, 91
Muscarinic cholinergic system 55–8
Mustards
  adverse effects 6, 7
  formulae 5
  nucleic acid interaction 6
  pharmacology 5
  in psoriasis 4–7
Mycophenolic acid 8
  adverse reactions 11
  formulae 9
  pharmacology 10
  in psoriasis 8–11
  site of action 9, 10

Na^++K^+–ATPase, cardiac glycoside target 394
Nervous system, ethanol effects 431–52
Nitroimidazole radiosensitizers 197–213
  chemical synthesis 198–209
  preparation, clinical interest 212, 213
2-Nitroimidazoles
  chemical synthesis 198–202
  chemistry 210
4- and 5-Nitroimidazoles
  chemical synthesis 202–9
  chemistry 211

Nociception *see also* pain
  brain lesions 183, 184
  hypophysectomy 184
  opiate receptor role 177–88
  opioid modifiers 179–83
Norepinephrine
  fetal atrial rate 58
  mouse heart development 81

Oligopeptide transport system 298, 299
Opiate antagonists, pronociceptive effects 179–83
Opiate receptors
  distribution 178, 179
  and nociception 177–88
Opioid analgesia 185
Opioid modifiers and nociception 179–83
Oral retinoids
  acne 365–7
  Darier's disease 365
  psoriasis 363–5
  psoriasis chemotherapy 355–70
  side effects 369, 370
  skin action 360–2
Osteoarthritis assessment and drugs 484

Pain *see also* nociception
  assessment 478
  congenital insensitivity 187
  peripheral and central pathways 459–68
Peptidoglycan
  D-ala–D-ala inhibition 282
  D-alanine analogue uptake 276, 281
  D-amino acid inhibition 288, 289
  analogue inhibition mechanism 278
  conformational energy and crosslinking 284
  crosslinkage 283
  glycine, alanine and cross linking 286
  glycine substitution for alanine 283
Peripheral neural substances in pain
  conduction velocity 460
  morphology 459, 460
  responses, cardiac muscle 462
    cutaneous 461
    skeletal muscle 461
    teeth 462
Phosphonodipeptides, antibacterial activities 301
Phosphono-oligopeptides, antibacterial activity 302
Placental drug transfer 375–87
  antibiotics 383
  autonomic nervous system drugs 381–3
  CNS drugs 380, 381
  fluoride transfer 378–80
  hormones 383, 384
  ion transfer 378–80
  local anesthetics 381, 382
  maternal–fetal drug distribution 376, 377
  organomercury 383
  pharmacokinetics 375–8
  saccharin 385
Polymyalgia rheumatica assessment 490
Porokeratosis mibelli, oral retinoids 367, 368
Prodrugs 25–51
  activity 25
  candidates 27
  compartment models 28–34
  design and evaluation 47–51
  examples 26
  goals 26
  improved formulation 49
  increased duration 49

increased oral absorption 48, 49
multiple dose equations 45, 46
optimum lability of linkage 43–5
pharmacokinetic analysis 47
pharmacokinetics 28–46
plasma drug concentration prolongation 37–43
pre-systemic metabolism 43
reviews 27, 28
site specificity 51
systemic conversion, rapid 34–7
Progesterone, digitalis-like properties 398, 399
Pro-opiocortin hormones, physiology and biochemistry 162
Propranolol
indicator diffusion 220
solute extraction 221
Protein binding, drugs 329–32
Protein kinase
cardiac ontogenesis 61
neonatal and adult isoenzymes 61, 62
Psoriasis
arthritis 348
autoantibodies 348–50
cell mediated immunity 350
chemotherapy, oral retinoids 355–70
granulocyte function 351
histopathology 346, 347
HLA associations 347, 348
immunology 345–52
oral retinoids 363–5
systemic chemotherapy 8–19
topical agents 2–7
6-Pteridyl aldehyde
formula 253
xanthine oxidase inhibition 253–7
6-Pteridyl carboxylic acid, xanthine oxidase inhibition 253–7

Quinuclinyl benzilate, muscarinic cholinergic receptor measure 56–9

Radiosensitizors, nitroimidazole 197–213
Receptor, digitalis 391–4
Retinoic acid, fecal metabolites 358
Retinoids *see also* oral retinoids
clinical application 363–70
effects of toxic doses 361
RO 10-9359, metabolites 359
synthetic 357–60
therapeutic indices 358
Rheumatic fever, assessment 490
Rheumatoid arthritis
drug action assessment 477–84
functional capacity 480
hematological indices 481–3
immunological tests 483, 484
physical signs 479
radiology 481
stiffness 478
symptom assessment 478
tests, clinical and laboratory 479, 480

Seronegative arthropathies, assessment 487, 488
Sodium pump, cardiac glycoside target 394–6
Spinal cord, laminae I–V 463–64
Steroids, amphibian, digitalis-like properties 397
Suppressor cell differentiation, drug effects 97–101
Supraspinal sites in pain 467, 468
cortex 468
diencephalon 467, 468
medullary reticular formation 467
Systemic lupus erythematosus assessment 488, 489

Theophylline, fetal heart responses 63–5
Thermography, inflammation assessment in rheumatoid arthritis 479, 480
Toxicology of molluscicides 67–84
Trifenmorph 67–84
analysis in water 80
biological effects 82–4
carcinogenicity 76, 77
environmental fate 80–2
field evaluation 71–4
mammalian toxicology 74, 75
metabolic studies 75, 76
mode of action in snails 77–9
molluscicidal activity 69–74
molluscicidal activity in laboratory 69–71
mutagenicity 76, 77
particle size and effects 68
stability 68
stability in water 79, 80
teratogenicity 76, 77
Trigeminal substrates in pain 466
Tyramine and fetal heart rate 60

UDP–MurNAc–Ala–DGlu–Lys–DAla–DAla
incorporation time course 281
specificity profile 280
structure 279

Vanadate, digitalis-like properties 392, 393, 400, 401
Vitamin A 355
compounds 356
metabolism 356, 357

Xanthine oxidase inhibitors 249–61
active site models 258, 259
mechanism of action model 256
purine analogues 250–7
reactions catalysed 249
tight binding 249–61